Novo Nordisk A/S (NYSE:NVO) Stock Rating Upgraded by Sanford C. Bernstein

Novo Nordisk A/S (NYSE:NVO) was upgraded by research analysts at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research report issued on Monday.

A number of other analysts have also commented on NVO. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $2.39 during mid-day trading on Monday, reaching $85.26. The stock had a trading volume of 5,344,828 shares, compared to its average volume of 4,406,944. The firm has a market cap of $382.61 billion, a PE ratio of 27.59, a P/E/G ratio of 1.37 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s 50 day simple moving average is $103.06 and its 200 day simple moving average is $121.08. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15.

Institutional Trading of Novo Nordisk A/S

Several hedge funds have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth about $2,722,000. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $86,000. Confluence Investment Management LLC lifted its stake in Novo Nordisk A/S by 2.2% in the 4th quarter. Confluence Investment Management LLC now owns 10,274 shares of the company’s stock valued at $884,000 after purchasing an additional 220 shares during the last quarter. American Trust boosted its position in Novo Nordisk A/S by 139.1% in the third quarter. American Trust now owns 12,725 shares of the company’s stock valued at $1,515,000 after buying an additional 7,402 shares in the last quarter. Finally, Tri Ri Asset Management Corp acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $17,276,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.